Mid career · publishing since 2007Rising activity
Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchRadiopharmaceutical Chemistry and ApplicationsCAR-T cell therapy researchAdvanced Biosensing Techniques and Applications
Publications
177
Citations
4,730
Est. group size
~15
Recurring co-author estimate
Active years
21
Publishing since 2007
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 4,730p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 21.6p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~6 · 21% small-team papers (≤3 authors) · across 29 venues
Publication cadence
Publications per year over the last 10 years — averaging 21.6/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Data for: Dual cancer-selective lysosomally-targeted antibody–drug conjugates expand the ADC-druggable proteome
Zenodo (CERN European Organization for Nuclear Research) · 2027
- Data for: Dual cancer-selective lysosomally-targeted antibody–drug conjugates expand the ADC-druggable proteome
Zenodo (CERN European Organization for Nuclear Research) · 2027
- Oral Administration of a Bivalent Carbonic Anhydrase IX Near-Infrared Imaging Agent Detects Hypoxic Tumors in a Mouse Model
ACS Sensors · 2026
- Figure S7 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S6 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S4 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Data from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S5 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S9 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S11 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S12 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S8 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S10 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S2 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
- Figure S1 from <i>In Vivo</i> Auto-tuning of Antibody–Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies
2026
Publishes in
- The AAPS Journal×6
- Molecular Cancer Therapeutics×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Journal of Nuclear Medicine×4
- Scientific Reports×3
Similar researchers
By research-topic overlap
- Anna Kopp
Medicine · University of Michigan
- Alec A. Desai
Medicine · University of Michigan
- Eshita Khera
Medicine · University of Michigan
- James R. Baker
Medicine · University of Michigan
- Jamison Grailer
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile